Pulmonary and systemic circulatory effects of midodrine, a new sympathomimetic, and its metabolite, ST 1059.
D000316:Adrenergic alpha-Agonists / Q000494:pharmacology*; D000818:Animals; D001783:Blood Flow Velocity; D001794:Blood Pressure / Q000187:drug effects; D002302:Cardiac Output / Q000187:drug effects; D002404:Catheterization; D004285:Dogs; D004983:Ethanolamines / Q000494:pharmacology*; D005260:Female; D005998:Glycine / Q000494:pharmacology; D006339:Heart Rate / Q000187:drug effects; D006873:Hydroquinones / Q000494:pharmacology; D008168:Lung / Q000098:blood supply; D008297:Male; D008729:Methoxamine / Q000494:pharmacology; D012039:Regional Blood Flow / Q000187:drug effects; D013997:Time Factors; D014628:Vagotomy; D014630:Vagus Nerve / Q000502:physiology; D014655:Vascular Resistance / Q000187:drug effects; D014662:Vasoconstrictor Agents / Q000494:pharmacology
D000316:Adrenergic alpha-Agonists; D004983:Ethanolamines; D006873:Hydroquinones; D014662:Vasoconstrictor Agents; D008729:Methoxamine; D005998:Glycine